Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody

Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody

Good pharmacokinetic (PK) behavior is a key prerequisite for sufficient efficacy of therapeutic monoclonal antibodies (mAbs). Fc glycosylation is a critical quality attribute (CQA) of mAbs, due to its impact on stability and effector functions. However, the effects of various IgG Fc glycoforms on an...

Full description

Bibliographic Details
Main Authors: David Falck, Marco Thomann, Martin Lechmann, Carolien A. M. Koeleman, Sebastian Malik, Cordula Jany, Manfred Wuhrer, Dietmar Reusch
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
Pharmacokinetics
N-glycosylation
monoclonal antibodies
liquid chromatography – mass spectrometry
glycoengineering
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2020.1865596

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2020.1865596

Similar Items